Literature DB >> 10964858

Timing of onset of antidepressant response with fluoxetine treatment.

A A Nierenberg1, A H Farabaugh, J E Alpert, J Gordon, J J Worthington, J F Rosenbaum, M Fava.   

Abstract

OBJECTIVE: The purpose of this study was to assess the time until onset of antidepressant response with fluoxetine treatment.
METHOD: The authors evaluated 182 outpatients with major depression who had a sustained acute response to fluoxetine treatment. The outpatients received 8 weeks of treatment with 20 mg/day of fluoxetine and were assessed biweekly with the 17-item Hamilton Depression Rating Scale. The onset of response was defined as a 30% decrease in score on the Hamilton depression scale that persisted and led to a 50% decrease by week 8. The Kaplan-Meier product limit and Cox regression analysis were used to model the relationship between relevant variables and time until onset of response.
RESULTS: The authors found that at weeks 2, 4, and 6, the probabilities of having an onset of response (for responders) were 55.5%, 24.7%, and 9.3%, respectively. The cumulative probabilities of onset of response at each time point were 55.5%, 80.2%, and 89.5%. Neither demographics nor clinical characteristics of depression predicted time until initial response.
CONCLUSIONS: These data suggest that more than half of eventual responders to fluoxetine treatment at 8 weeks start to respond by week 2; over 75% start to respond by week 4. Conversely, the lack of onset of response at 4-6 weeks was associated with about a 73%-88% chance that patients would not have an onset of response by 8 weeks.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964858     DOI: 10.1176/appi.ajp.157.9.1423

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  47 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.

Authors:  Stella Bitran; Amy H Farabaugh; Victoria E Ameral; Rachel A LaRocca; Alisabet J Clain; Maurizio Fava; David Mischoulon
Journal:  Int Clin Psychopharmacol       Date:  2011-07       Impact factor: 1.659

3.  Addressing both depression and pain in late life: the methodology of the ADAPT study.

Authors:  Jordan F Karp; Bruce L Rollman; Charles F Reynolds; Jennifer Q Morse; Frank Lotrich; Sati Mazumdar; Natalia Morone; Debra K Weiner
Journal:  Pain Med       Date:  2012-02-07       Impact factor: 3.750

4.  Onset of action of antidepressants.

Authors:  Andre Tylee; Paul Walters
Journal:  BMJ       Date:  2007-05-05

5.  Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial.

Authors:  André Tadić; Stanislav Gorbulev; Norbert Dahmen; Christoph Hiemke; Dieter F Braus; Joachim Röschke; Dietrich van Calker; Daniel Wachtlin; Kai Kronfeld; Thorsten Gorbauch; Monika Seibert-Grafe; Klaus Lieb
Journal:  Trials       Date:  2010-02-26       Impact factor: 2.279

6.  Initial rate of improvement in relation to remission of major depressive disorder in primary care.

Authors:  Anton C Vergouwen; Huibert Burger; Frank Koerselman; Theo J Verheij
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

7.  Effects of Restricted Time in Bed on Antidepressant Treatment Response: A Randomized Controlled Trial.

Authors:  J Todd Arnedt; Leslie M Swanson; Richard R Dopp; Holli S Bertram; Ann J Mooney; Edward D Huntley; Robert F Hoffmann; Roseanne Armitage
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

Review 8.  Pharmacotherapy to sustain the fully remitted state.

Authors:  Sidney Kennedy; Roger McIntyre; Angelo Fallu; Raymond Lam
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

Review 9.  An update on antidepressant use in bipolar depression.

Authors:  Michelle M Sidor; Glenda M MacQueen
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

10.  Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.

Authors:  Daniel Z Lieberman; Suena H Massey
Journal:  Core Evid       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.